health care

The report focuses on five possible future scenarios for African healthcare systems over the next ten years. Thirty-four leading healthcare experts, representing the entire chain of stakeholders across the sector, helped the editors identify the key trends shaping African healthcare systems.

Jane Griffiths, Company Group Chairman of Janssen in EMEA, explains : “The study draws a very high level picture, combining statistics with trends and possible scenarios that could form the basis for further discussions on which policy options to take. Solutions can only become clearer by having open and constructive discussions with all parties involved, based on factual analyses”.

Janssen is active in Africa in many ways. Apart from selling its products across the region, the company has also set up a number of projects specifically designed for infectious and neglected diseases, including research for a new tuberculosis treatment in collaboration with the TB Alliance, a microbicide targeting HIV, with the International Partnership for Microbicides, a new research programme against elephantiasis and river blindness with the Drugs for Neglected Diseases initiative (DNDi) and the Gates Foundation, as well as against sleeping sickness, Chagas and visceral leishmaniasis.

For the products that are already approved, Janssen sets up access programmes, such as the recently concluded agreements with generic manufacturers in Africa to distribute the company’s HIV/AIDS compounds, or the free distribution of treatments against intestinal infections with the Children Without Worms programme.